Current Research: Medical Oncology

Back to Medical Oncology Research


S0226 -- Anastrozole Vs Anastrozole + Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer

The purpose of this study is to find out what effects (good or bad) the combination of hormonal agents anastrozole and fulvestrant have over anastrozole alone on breast cancer.

Both drugs anastrozole and fulvestrant are approved by the FDA for the treatment of metastatic breast cancer. However, it is the combination of the two drugs that is considered experimental.


Eligibility

You may be eligible for this trial if:

  • You are female and postmenopausal
  • You have metastatic breast cancer
  • You are ER or PgR positive
  • Your prior adjuvant or neoadjuvant chemo has been completed at least 12 months prior to registration
  • You have measurable or non-measurable disease

Trial Sponsor

  • Southwest Oncology Group (SWOG)

Project Begin Date

  • Nov 2005

Tentative Project End Date

  • Jan 2011

Back to Medical Oncology Research

Revised April 14, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .